April 2014 Issue Table Of Contents

From The Editor

• Are You Embracing The Life Sciences New Innovation Ecosystem?

Feature

• Merck Serono’s CEO Belén Garijo – Enabling Risk And Refusing To Play It Safe

Capitol Perspectives

• Partisanship Scuttles Bipartisan Reform Of SGR

Companies To Watch

• Synthetic Biologics: A Developer Of New Biologics Focused On Serious Infections

Outsourcing Insights

• New Technologies In Fill-Finish May Bring Brand Loyalty With Improved Patient Safety

Bio Innovation notes

• Biopharma Quality Management Best Practices: An Approach To Quality Initiatives

Roundtable

• The Art Of Optimizing Small Biotech Market Caps – From Scientific Dreams To Strategic Reality

Inside The Industry

• VAT and The Clinical Trial Enterprise
• Antibiotic R&D Gains Traction: A Mid-Cap Company Leads The Way
• Are You Prepared For The New European Pharmacovigilance Guidelines?
• 6 Steps For A Sustainable Approach To R&D Through Big Data

Industry Leader

• The FDA ’s Focus On Metrics, Performance, And Quality

Leadership Lessons

• Leadership Rules For The News Normal

Ask The Board

• Brand Protection Investments, Mentoring Mistakes, and Single-use Manufacturing